These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

284 related items for PubMed ID: 31536852

  • 21. Survival of advanced/recurrent gastrointestinal stromal tumors treated with tyrosine kinase inhibitors in Taiwan: a nationwide registry study.
    Tsai HJ, Shan YS, Yang CY, Hsiao CF, Tsai CH, Wang CC, Lin MT, Ting CF, Chan DC, Chen TH, Yen CC, Chen YY, Lin HY, Yeh TS, Ho CL, Shieh TY, Bai LY, Hsu JT, Chen IS, Chen LT, Yeh CN, Taiwan Cooperative Oncology Group (TCOG) GIST Study Group.
    BMC Cancer; 2024 Jul 11; 24(1):828. PubMed ID: 38992597
    [Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24. Regorafenib: a guide to its use in advanced gastrointestinal stromal tumor (GIST) after failure of imatinib and sunitinib.
    Lyseng-Williamson KA.
    BioDrugs; 2013 Oct 11; 27(5):525-31. PubMed ID: 23975637
    [Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27. TAS-116 inhibits oncogenic KIT signalling on the Golgi in both imatinib-naïve and imatinib-resistant gastrointestinal stromal tumours.
    Saito Y, Takahashi T, Obata Y, Nishida T, Ohkubo S, Nakagawa F, Serada S, Fujimoto M, Ohkawara T, Nishigaki T, Sugase T, Koh M, Ishida T, Tanaka K, Miyazaki Y, Makino T, Kurokawa Y, Nakajima K, Yamasaki M, Hirota S, Naka T, Mori M, Doki Y.
    Br J Cancer; 2020 Mar 11; 122(5):658-667. PubMed ID: 31857719
    [Abstract] [Full Text] [Related]

  • 28. Regorafenib: a novel multitargeted tyrosine kinase inhibitor for colorectal cancer and gastrointestinal stromal tumors.
    Crona DJ, Keisler MD, Walko CM.
    Ann Pharmacother; 2013 Dec 11; 47(12):1685-96. PubMed ID: 24259629
    [Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35. Pimitespib in patients with advanced gastrointestinal stromal tumor (CHAPTER-GIST-301): a randomized, double-blind, placebo-controlled phase III trial.
    Kurokawa Y, Honma Y, Sawaki A, Naito Y, Iwagami S, Komatsu Y, Takahashi T, Nishida T, Doi T.
    Ann Oncol; 2022 Sep 11; 33(9):959-967. PubMed ID: 35688358
    [Abstract] [Full Text] [Related]

  • 36. [A case of a gastrointestinal stromal tumor of the rectum effectively treated with continuously-administered regorafenib after failure of imatinib and sunitinib].
    Kajiura S, Hosokawa A, Nanjyo S, Nakada N, Ando T, Sugiyama T.
    Nihon Shokakibyo Gakkai Zasshi; 2016 Apr 11; 113(4):655-61. PubMed ID: 27052395
    [Abstract] [Full Text] [Related]

  • 37. Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumor after failure with imatinib and sunitinib treatment: A meta-analysis.
    Zhang Z, Jiang T, Wang W, Piao D.
    Medicine (Baltimore); 2017 Dec 11; 96(48):e8698. PubMed ID: 29310342
    [Abstract] [Full Text] [Related]

  • 38. Systemic therapy of advanced/metastatic gastrointestinal stromal tumors: an update on progress beyond imatinib, sunitinib, and regorafenib.
    Mohammadi M, Gelderblom H.
    Expert Opin Investig Drugs; 2021 Feb 11; 30(2):143-152. PubMed ID: 33252274
    [Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40. Long-term survival outcome with tyrosine kinase inhibitors and surgical intervention in patients with metastatic or recurrent gastrointestinal stromal tumors: A 14-year, single-center experience.
    Kim JH, Ryu MH, Yoo C, Chae H, Na H, Beck M, Kim BS, Yoo MW, Yook JH, Kim BS, Kim KH, Kim CW, Kang YK.
    Cancer Med; 2019 Mar 11; 8(3):1034-1043. PubMed ID: 30693663
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 15.